国际麻醉学与复苏杂志   2015, Issue (6): 5-5
    
右美托咪定对小儿鼾症手术苏醒期不良事件的影响
干晗, 江来1()
1.上海交通大学医学院附属新华医院
The effect of dexmedetomidine on adverse events during recovery period in children with obstructive sleep apnea syndrome operation
 全文:
摘要:

目的 观察右美托咪定对小儿鼾症手术苏醒期不良事件的影响。 方法 选取年龄2岁~6岁,美国麻醉医师协会(ASA)分级Ⅰ~Ⅱ级,拟在全麻下行扁桃体切除术和腺样体吸割术的鼾症患儿120例,采用随机数字表法分为3组:右美托咪定组(D组)、咪达唑仑组(M组)和对照组(P组),每组40例。患儿入室后均开放外周静脉,监测心率(heart rate, HR)、平均动脉压(mean arterial pressure, MAP)、脉搏血氧饱和度(pulse oxygen saturation, SpO2)、呼气末二氧化碳分压(partial pressure of end-tidal carbon dioxide, PETCO2)和脑电双频指数(bispectral index, BIS)。麻醉诱导采用咪达唑仑、丙泊酚、瑞芬太尼和罗库溴铵,术中以丙泊酚、瑞芬太尼靶控输注维持,D组、M组、P组患儿在手术结束前20 min分别静脉输注右美托咪定0.4 μg/kg、咪达唑仑0.05 mg/kg、0.9%氯化钠溶液0.1 ml/kg,10 min输注完毕。记录患儿麻醉前(T0),使用相应药物前(T1),使用相应药物结束后1(T2)、5 min(T3)、拔管前1 min(T4),拔管后即刻(T5)及拔管后3(T6)、5(T7)、10(T8)、20 min(T9)各时点的HR、MAP,并记录拔管时间、苏醒时间及苏醒期不良事件的发生率。 结果 M组的苏醒时间[(14±4) min]较P组[(11±4) min]和D组[(12±4) min]明显延长(P<0.05),而M组到达恢复室即刻改良Aldrete评分(6分)明显低于P组(8分)和D组(8分)(P<0.05);D组在T2~T8时点的HR[(95±16)、(96±16)、(101±17)、(103±17)、(101±16)、(100±16)、(101±17) 次/min]和MAP[(73±10)、(71±9)、(78±10)、(79±11)、(77±10)、(77±10)、(75±10) mmHg(1 mmHg=0.133 kPa)]明显低于M组和P组(P<0.05);D组的喉痉挛发生率(5%)、喉痉挛评分(0)、呛咳评分(1分)、SpO2下降至92%以下的发生率(5%)明显低于M组和P组(P<0.05),D组的屏气发生率(12.5%)明显低于P组(P<0.05);D组和M组的儿童麻醉后躁动(pediatric anesthesia emergence delirium, PAED)评分在进入苏醒室后10(8分和9分)、20 min(9分和10分)和30 min(8分和9分)明显低于P组(P<0.05)。 结论 在手术结束前静脉输注右美托咪定能有效减少小儿鼾症手术苏醒期不良事件的发生,且不造成拔管和苏醒延迟。

关键词: 右美托咪定; 咪达唑仑; 苏醒期; 不良事件; 鼾症
Abstract:

Objective To investigate the effects of dexmedetomidine on adverse events during recovery period in children with obstructive sleep apnea syndrome operation. Methods One hundred and twenty ASA physical status Ⅰ-Ⅱ children, aged 2 y-6 y, undergoing general anesthesia for tonsillectomy and adenoidectomy, were randomly divided into 3 groups (n=40): group D, group M and group P. Heart rate(HR), mean arterial pressure(MAP), pulse oxygen saturation(SpO2), partial pressure of end-tidal carbon dioxide(PETCO2) and bispectral index(BIS) were monitored in all patients when arriving in the operation room, and a intravenous catheter was inserted into the peripheral vein. The children were administered with midazolam, propofol, remifentanil and rocuronium for induction, while remifentanil and propofol target-controlled infusion for maintenance. Twenty min before the end of the surgery, in group D dexmedetomidine 0.4 μg/kg and in group M midazolam 0.05 mg/kg and in group P 0.9% NaCl were infused intravenously within 10 min. HR and MAP were recorded before anesthesia(T0), before intravenous administration(T1) , 1 min(T2) and 5 min(T3) after administration, 1 min before extubation(T4), the moment(T5), 3 (T6), 5 (T7), 10 (T8), 20 min(T9) after extubation. Time to extubation and emergence, the incidence of adverse events during recovery period were recorded. Results Time to emergence in group M[(14±4) min] were significantly longer than in group D [(11±4) min] and group P[(12±4) min](P<0.05) while the modified Aldrete score after entrance into PACU(6) were significantly lower (P<0.05). HR[(95±16), (96±16), (101±17), (103±17), (101±16), (100±16), (101±17) bpm] and MAP[(73±10), (71±9), (78±10), (79±11), (77±10), (77±10), (75±10) mmHg(1 mmHg=0.133 kPa)] were significantly lower at T2-T8 in group D compared with group M and group P(P<0.05), and the incidence of laryngospasm(5%), oxygen desaturation<92%(5%) and laryngospasm score(0), cough score(1) were also significantly lower in group D (P<0.05). The incidence of breath holding in group D(12.5%) was significantly lower than in group P (P<0.05). The pediatric anesthesia emergence delirium(PAED) scale at 10 min(8 and 9), 20 min(9 and 10) and 30 min(8 and 9) after entrance into post-anesthesia care unit(PACU) were significantly lower in group D and group M compared with group P(P<0.05). Conclusions Without interfering in recovery time,dexmedetomidine infused 20 min before the end of surgery effectively reduces adverse events during recovery period in children with obstructive sleep apnea syndrome.

Key words: Dexmedetomidine; Midazolam; Recovery period; Adverse events; Obstructive sleep apnea syndrome